Search results
Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel
Marketing Sentinel· 3 days agoIn today’s recent session, 2.33 million shares of the Merck & Co Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share ...
Earnings call: Merck sees organic growth despite market challenges By Investing.com
Investing.com· 15 hours agoMerck & Co., Inc. (MRK) reported its first-quarter results for 2024, revealing a slight decline in...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 3 days agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential
FierceBiotech· 18 hours agoWhat a time to be launching a new biotech focused on inflammation and immunology. Uniquity Bio is...
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks via Yahoo Finance· 15 hours agoToday's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
...Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - ...
Benzinga· 3 days agoMonday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
Clinical Trials Arena via Yahoo Finance· 2 days agoUS pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 6 days agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 3 days agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the ...
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 2 days agoWith Merck’s growth largely depending on Keytruda, the recent pipeline setbacks do not bode well for...